2021-04-07

[#DIV28SUPER] Fwd: [OSNN] Stigma of Addiction Summit - June 10 - Register and Abstracts!



Hello Division 28 Colleagues,

Please see below a free summit related to the stigma of addiction. -

Warm regards,
Kelly Dunn


Registration now open: half-day action-oriented virtual summit on eradicating addiction stigma


Stigma of Addiction Summit
Free Virtual Symposium

 
June 10, 2021 | 12:00pm - 6:00pm ET
 
Register to Attend

Join the National Academy of Medicine, Dell Medical School at The University of Texas at Austin, and Shatterproof on June 10, 2021 for the Stigma of Addiction Summit - a half-day, virtual, action-oriented summit entirely dedicated to understanding, addressing, and eliminating the harmful impacts of stigma on people who use drugs. 

The Summit will endeavor to elevate current efforts at reducing stigma, identify successes and gaps in the evidence base, and prioritize and identify areas for future research and funding with an explicit focus on stigma, which is often touched upon only marginally in broader conversations about addiction. 

The Summit has been organized by an interprofessional and interdisciplinary planning committee of people in recovery, clinicians, health profession educators, addiction medicine professionals, government stakeholders, and health professional organizations.


The Summit is free to attend and will be recorded for viewing after the event concludes. 
 
Register to Attend

Call for Innovation Abstracts!

As part of the Stigma of Addiction Summit, the planning committee is announcing a call for innovation abstracts, intended to help promote promising initiatives that may not yet have received funding or been adopted broadly, and also to promote a broader network among those who are working to reduce stigma of people who use drugs. 

We invite individuals, teams, and organizations to submit abstracts showcasing programs, initiatives, strategies, research, courses, products, or solutions about reducing stigma of people who use drugs. 

The application period will remain open until April 23. Accepted abstracts will be published in a free-to-access Summit compendium and selected authors may be asked to share their work in a pre-recorded video that will be shown live at the Summit on June 10. 
 
Learn more and submit today!
Help us spread the word!  

 Tweet this!  The #StigmaSummit is a half-day, virtual, action-oriented symposium focused on understanding, addressing, and eliminating the harmful impacts of stigma on those who use drugs and experience addiction. Join us: https://nam.edu/event/stigma-of-addiction-summit/

 Tweet this! Join @theNAMedicine @DellMedSchool @Shatterproofhq for a half-day virtual summit on 6/10 to hear about how stigma manifests in health care, how to intervene in real time, and the role of advocates and families: https://nam.edu/event/stigma-of-addiction-summit/ #StigmaSummit

  Tweet this!  Do you have a promising approach to eradicating the stigma experienced by people who use drugs and experience addiction? Submit it to the #StigmaSummit's call for innovation abstracts by 4/23! https://nam.edu/event/stigma-of-addiction-summit/
Download the graphics below and share them on social media! 







--
Kelly Dunn, Ph.D., MBA
Associate Professor
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
BPRU Phone: (410) 550-2254
Fax: (410) 550-0030
 
WARNING:  E-mail sent over the Internet is not secure.  Information sent by e-mail may not remain confidential.
DISCLAIMER:  This e-mail is intended only for the individual to whom it is addressed.  It may be used only in accordance with applicable laws.  If you received this e-mail by mistake, notify the sender and destroy the e-mail

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2021-04-06

[#DIV28SUPER] Matt Field Seminar Sponsored by University of Florida Center for Behavioral Economic Health Research - Thursday @ 4pm

Dear Division 28 Members, 

Dr. Matt Field will be giving a talk this week via zoom (Thursday April 8 @ 4:00 pm ET) on choice and compulsion in addiction. Please see below for the flier/information and if interested, please register in advance by clicking on the link below. 

Best, 
Meredith

 

 

 

 

April 8 Seminar, 4:00 p.m. EDT:

Choice and Compulsion in Addiction and Recovery

 

Matt Field, Ph.D., Professor of Psychology, University of Sheffield, United Kingdom

 

Dr. Field is an internationally recognized expert on the psychological mechanisms that underlie alcohol problems and other addictions with emphasis on the role of decision-making and impulse control in addiction, recovery, and behavior change more broadly. He conducts laboratory research to investigate determinants of motivated behavior and works with people with alcohol problems to study the process of recovery and to investigate novel translational treatments.

 

Register in advance for this meeting:

https://ufl.zoom.us/meeting/register/tJEkc-qspjwrHdX241mRkyh8ZBOhCq1CN7tL

 

Website:

http://hhp.ufl.edu/faculty-research/centers-institutes/cbehr/

Phone:   (352) 294-1617

Email: cbehr@hhp.ufl.edu

 

 

 

 

 

 

 

2021-04-03

[#DIV28SUPER] NOT-OD-21-066: Request for Information (RFI): Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research

Dear Colleague,

 

Your response to this Request for Information (RFI) by April 9, 2021 will be greatly appreciated.  All comments must be submitted electronically on the submission website.

Please send to interested parties.

 

Request for Information (RFI): Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-066.html

Notice Number:

NOT-OD-21-066

Key Dates

Release Date:

March 1, 2021

Response Date:

April 09, 2021

Related Announcements

None

Issued by

Office of The Director, National Institutes of Health (OD)

Purpose

This Notice is a Request for Information (RFI) inviting feedback on the approaches NIH can take to advance racial equity, diversity, and inclusion within all facets of the biomedical research workforce, and expand research to eliminate or lessen health disparities and inequities.

Review of this entire RFI notice is encouraged to ensure a comprehensive response is prepared and to have a full understanding of how your response will be utilized.

Background

The ability of NIH to remain at the forefront of biomedical research and to ensure that scientific discoveries truly benefit all depends upon diverse skill sets, viewpoints, and backgrounds. Events of the past year sparked a national discourse around social justice and systemic racism, and have brought into focus ongoing inequities in biomedical research and healthcare – from training and recruitment to funding to the support and administrative functions, in addition to shaping the type of research supported. The notions of recruitment, training, and advancement equally apply to the support and administrative staff that sustain the research enterprise, without whom NIH could not achieve its mission. Further, COVID-19 has amplified existing systemic challenges regarding prevalence, diagnosis, and treatment of illness within historically marginalized and under-resourced communities, as the disease is disproportionally affecting under-resourced and vulnerable populations, particularly those from Black/African American, American Indian/Alaska Native, and Hispanic/Latino populations. As a global leader in biomedical research, NIH carries a weighted responsibility to address the systemic challenges and barriers affecting the NIH workforce and NIH-supported biomedical community that hinder the progress necessary to support true health equity. Enhancing workforce diversity and equity across the biomedical enterprise are critical steps to achieving progress. NIH acknowledges the experiences of those affected by race-based discrimination and is committed to eliminating racial and ethnic inequities within our workplace, the NIH-supported external scientific workforce, and the NIH-funded research portfolio. NIH leadership established the UNITE initiative, a new effort that involves all 27 NIH Institutes and Centers and the Office of the Director, to promote and advance racial equity, diversity, and inclusion. Ultimately, NIH strives to foster a biomedical research community and an NIH workplace that are free from hostility and discrimination grounded in race, sex, or other federally protected characteristics. In addition, NIH seeks to promote research to inform and address the breadth of health disparities/inequities, which continue to contribute to increasing morbidity and mortality. The current priorities of the UNITE effort are outlined below:

Priorities

  • Listen, learn, and articulate findings
  • Engage internal and external communities
  • Change culture to promote equity, inclusivity, and justice
  • Improve policies, transparency, and oversight
  • Strengthen career pathways, training, mentoring, and the professoriate
  • Ensure fairness in review and funding deliberations
  • Enhance funding and research support for diverse institutions and historically under-resourced research areas

Request for Comments

To ensure that the broad perspective of the biomedical research community informs the development of and aligns with NIH’s future plans and approaches, this RFI invites stakeholders throughout the scientific research, advocacy, clinical practice, and non-scientific communities, including the general public, to comment. In particular, NIH is interested in comments from higher education administrators, undergraduate and graduate students, postdoctoral scientists, biomedical faculty (especially early stage), scientific societies and advocacy organizations, community partners, academic institutions (especially Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions (HSIs), Tribal Colleges and Universities (TCUs), and other institutions that have shown a historical commitment to educating students from underrepresented groups), and racial equity organizations on strategies to enhance equity, diversity, and inclusion within the scientific workforce and advance health disparities research.

Specifically, with this RFI, NIH seeks input on practical and effective ways to improve the racial and ethnic diversity and inclusivity of research environments and diversity of the biomedical research workforce across the United States, to the extent permitted by law. This RFI will assist NIH in identifying, developing, and implementing strategies that will allow the biomedical enterprise to benefit from a more diverse and inclusive research workforce and a more robust portfolio of research to better understand and address inequities in our existing system. While it will be important to understand further the fundamental and systemic barriers, the primary focus of this RFI is on the actions and solutions – through policy, procedure, or practice – NIH should consider in order to promote positive culture and structural change through effective interventions, leading to greater inclusiveness and diversity. Please also include potential metrics for evaluating success of the suggested actions or solutions, where possible. Input is requested on approaches and strategies that can be implemented in the short-term (e.g., within the next three to six months), as well as those that can be implemented within the next one to three years.

The NIH seeks comments on any or all of, but not limited to, the following topics:

All Aspects of the Biomedical Workforce

  • Perception and reputation of NIH as an organization, specifically as an employer (e.g., culture), with respect to support of workforce diversity and as an overall advocate for racial and gender equity in NIH-funded research
  • New or existing influence, partnerships, or collaborations NIH could leverage to enhance its outreach and presence with regards to workforce diversity (both the internal NIH workforce and the NIH-funded biomedical research enterprise); including engagement with academic institutions that have shown a historical commitment to educating students from underrepresented groups (especially Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions (HSIs), Tribal Colleges and Universities (TCUs), and other institutions), racial equity organizations, professional societies, or other federal agencies
  • Factors that present obstacles to training, mentoring, or career path (e.g., training environments) leading to underrepresentation of racial and ethnic groups (particularly Black/African Americans) in the biomedical research enterprise throughout the educational and career continuum and proposed solutions (novel or proven effective) to address them
  • Barriers inhibiting recruitment and hiring, promotion, retention and tenure, including the barriers scientists of underrepresented groups may face in gaining professional promotions, awards, and recognition for scientific or non-scientific contributions (e.g., mentoring, committees), and proven strategies or novel models to overcome and eliminate such barriers
  • Successful actions NIH and other institutions and organizations are currently taking to improve representation, equity, and inclusion and/or reduce barriers within the internal NIH workforce and across the broader funded biomedical research enterprise

Policies and Partnerships

  • Existing NIH policies, procedures, or practices that may perpetuate racial disparities/bias in application preparations/submissions, peer review, and funding, particularly for low resourced institutions, and proposed solutions to improve the NIH grant application process to consider diversity, inclusion, and equal opportunity to participate in research (e.g., access to application submission resources, changes to application submission instructions/guidance, interactions with and support from NIH staff during application process)
  • Best practices or proven approaches to build new or enhance existing partnerships and collaborations between investigators from research-intensive institutions and institutions that focus on under-resourced or underrepresented populations but have limited research resources

Research Areas

  • Significant research gaps or barriers to expanding and advancing the science of health disparities/health inequities research and proposed approaches to address them, particularly those beyond additional funding (although comments could include discussion of distribution or focus of resources)

Further Ideas

  • Additional ideas for bold, innovative initiatives, processes or data-driven approaches that could advance the diversity, inclusion, and equity of the biomedical research workforce and/or promote research on health disparities

NIH encourages organizations (e.g., patient advocacy groups, professional organizations) to submit a single response reflective of the views of the organization or membership as a whole.

How to Submit a Response

All comments must be submitted electronically on the submission website.

Responses must be received by 11:59:59 pm (ET) on April 9, 2021.

Responses to this RFI are voluntary and may be submitted anonymously. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law.

Other than your name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information, the Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information.

We look forward to your input and hope that you will share this RFI opportunity with your colleagues.

Inquiries

Please direct all inquiries to: UNITEInitiative@nih.gov

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L

 

2021-04-02

[#DIV28SUPER] Call for Papers: Experimental and Clinical Psychopharmacology Special Issue

Call for Papers: Experimental and Clinical Psychopharmacology (Due: Oct 1, 2021)

Special Issue on Crowdsourcing Methods in Addiction Science: Emerging Research and Best Practices

This Special Issue will assemble a collection of papers on best practices and emerging research using crowdsourcing for addiction science. With the changing landscape of work amidst the global COVID-19 pandemic and increasing costs associated with collecting large participant samples, addictions researchers are increasingly turning to alternative methods for recruiting participants and collecting data. Crowdsourcing platforms—such as Amazon Mechanical Turk, Prolific, and Qualtrics Panels—have become a dominant form of sampling in recent years. These crowdsourcing platforms allow researchers to continue to collect data from large samples of human participants when face-to-face visits are challenging, cost-prohibitive, or infeasible (e.g., research sites at logistically prohibitive distances, social distancing requirements during COVID-19). Alongside optimism about the practical benefits that crowdsourcing may provide are uncertainties about the validity of these Internet-based approaches and how they can (and cannot) be used. Any articles addressing the use of crowdsourcing in addictions science are welcome, but three areas are of specific interest. First, the issue aims to provide an historical and contemporary overview of available crowdsourcing platforms and how these have been used in addiction and behavioral science research. Second, innovative examples of original research studies will be included to illustrate the unique promise of crowdsourcing. The third area of emphasis involves the potential pitfalls of using this technology for data collection and methods to ensure that data are reliable and valid. Taken together, the overarching goal of this Special Issue is to highlight best practices for using crowdsourcing in addiction science while also drawing attention to important methodological and conceptual limitations of this methodology.

We encourage submission of review articles and original research reports in these areas, including novel strategies or methodological advances in crowdsourcing research in addictions. Papers addressing a variety of substances, including alcohol, tobacco, cannabis, and other drugs, as well as behavioral addictions are welcome. Researchers in this area may submit their manuscripts to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), and the cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue: Crowdsourcing Methods in Addiction Science: Emerging Research and Best Practices. All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2021 will be considered for inclusion in the special issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft title and abstract.

Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Justin Strickland, PhD, at jstric14@jhmi.edu, Michael Amlung, PhD, at mamlung@ku.edu, or Derek Reed, PhD, at dreed@ku.edu, or the Editor, William W. Stoops, PhD at William.stoops@uky.edu.

 

 

---------------------------------------------------------
Justin C. Strickland, Ph.D.
Postdoctoral Fellow
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Phone: (410) 550-1975

He/him/his

 

 

2021-03-30

[#DIV28SUPER] Job Announcement: Friends Research Institute, Research/Senior Research Scientist

Hello Colleagues,

Please see the attached announcement for a job opening for Research or Senior Research Scientist at Friends Research Institute.

Warm regards,
Kelly

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030

[#DIV28SUPER] In memoriam, Dr. Mary Jeanne Kreek

Hello Division Colleagues

It is with great sadness that I am writing to share news of the tragic passing of Dr. Mary Jeanne Kreek. Dr. Kreek was a pillar in our field who helped advance addiction science and supported the career development of many of our leaders. She was known for her exemplary science and her mentorship, and was regarded highly throughout the field. She played a major role in shaping our understanding of addiction and the methods used to explore treatments. Her work undoubtedly paved the way for many of us to forge our own careers and led to the development of treatments that helped countless patients.  The Division 28 Executive Committee wishes to send condolences to her family and friends, and the many colleagues that had the privilege of knowing Dr. Kreek throughout her impactful career.

A description of her legacy is provided here and a statement from the President of Rockefeller University (shared from INRC) is provided below : https://www.rockefeller.edu/news/30284-mary-jeanne-kreek-pioneer-studies-addiction-died/

"Dear colleagues,

It is with great sadness that I share the news that Mary Jeanne Kreek, a beloved colleague and pioneering physician-scientist, passed away last night. Mary Jeanne was the Patrick E. and Beatrice M. Haggerty Professor and Head of the Laboratory of the Biology of Additive Diseases, as well as Senior Physician at the Rockefeller University Hospital. Mary Jeanne was a pioneer in the biology of addiction research and made seminal contributions that led to methadone's successful use as a treatment for heroin addiction. Beyond her scientific endeavors, she was a champion for her patients, often speaking out against the societal stigma they faced. And of course we all know her passion both for Rockefeller and for the breadth of biomedical science. Her unfailing attendance at Friday Lectures and other campus events, punctuated by incisive questions drawn from her long history in biomedicine, as well as her optimism and unwavering support for women in science are qualities we will not forget.

After graduating from Wellesley College, Mary Jeanne earned her MD degree from Columbia University College of Physicians and Surgeons. During her residency in internal medicine at what is now Weill Cornell Medical School, she first set foot on Rockefeller's campus for a research elective in Vincent Dole's lab, who was investigating the potential use of methadone in the treatment of heroin addiction. After residency she moved to Rockefeller in 1964 as an Associate Physician at the Rockefeller University Hospital to pursue these studies on addiction, and performed early studies with both Dole and Marie Nyswander that led to the hypotheses that addiction was a metabolic disorder in which addicts' brains are functionally altered, and that methadone could help mitigate the symptoms of addiction. In 1966, the trio published one of their first landmark papers showing that methadone could be used to fight heroin abuse.

This early success, large as it was, was only the beginning for Mary Jeanne. By the 70s, she had developed the first laboratory techniques for measuring methadone and similar drugs in blood and tissues. This contribution helped make possible the FDA's approval of methadone for opiate addiction. Mary Jeanne's research also facilitated the development of another drug, buprenorphine, which acts on the same receptor in the brain.

Mary Jeanne went on to become one of the first to document how drugs of abuse significantly alter gene expression in certain brain regions, resulting in neurochemical and behavioral changes. Developing animal models for addiction, and identifying many of the genes and biological pathways that act in concert to increase a person's likelihood of suffering from addiction were among Mary Jeanne's accomplishments. In recent years, her lab identified more than 100 genetic changes associated with addiction, some of which were also associated with atypical stress responses, findings that suggest a predisposition to become addicted.

Mary Jeanne has been recognized with numerous awards for her research, including the Betty Ford Award for impact on the field of alcohol and drug abuse in 1996; the Specific Recognition Award for Research in the Science of Addiction from the Executive Office of the President of the United States in 1998; the R. Brinkley Smithers Distinguished Scientist Award from the American Society of Addiction Research, and Nathan B. Eddy Memorial Award from the College on Problems of Drug Dependence, both in 1999; the Wellesley College Alumnae Achievement Award in 2012; and the Lifetime Science Award from the National Institute on Drug Abuse of the National Institutes of Health in 2014. She was the recipient of honorary degrees from Uppsala University, Sweden (2000), the University of Tel Aviv (2007), and the University of Bologna (2010). 

In 2017, Mary Jeanne was interviewed for an oral history of her life that included a short film distilled from those interviews, available at this linkhttps://www.rockefeller.edu/about/history/oral-history-project/interview-mary-jeanne-kreek/



Mary Jeanne will be remembered both for her dynamism as a scientist and her humanism as a physician, patient advocate, and mentor. 

Please join me in extending our community's deepest condolences to Mary Jeanne's family. She is survived by her two children: Her daughter Esperance Schaefer, with son-in-law Karl Welday and grandchildren Robert and Francine; and her son Robert Schaefer, with daughter-in-law Heather Fain Schaeffer and grandchildren Meryl and William.

Sincerely, 

Rick

Richard P. Lifton, M.D., Ph.D. 
Carson Family Professor
Laboratory of Human Genetics and Genomics
President
The Rockefeller University"


Kelly

---
Kelly Dunn, Ph.D., M.B.A.
President, Division on Psychopharmacology and Substance Use (Division 28)
American Psychological Association

Associate Professor
Behavioral Pharmacology Research Unit
Department of Psychiatry and Behavioral Sciences
Johns Hopkins School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
P:410-550-2254; F:410-550-0030